Citations

Clear

13 citation(s) found for "Huang, David T".

Risk Prediction in Male Adolescents With Congenital Long QT Syndrome: Implications for Sex‐Specific Risk Stratification in Potassium Channel‐Mediated Long QT Syndrome
Bjelic, Milica , Goldenberg, Ilan , Younis, Arwa , Chen, Anita Y. , Huang, David T. , Yoruk, Ayhan , Aktaş, Mehmet K. , Rosero, Spencer , Cutter, Kristina, McNitt, Scott , Sotoodehnia, Nona , Kudenchuk, Peter J. , Arking, Dan E. , Zaręba, Wojciech , Ackerman, Michael J. , Goldenberg, Ilan , Beinart, Roy , Arking, Dan E , Zareba, Wojciech , Ackerman, Michael J , Goldenberg, Ilan , Huang, David T , Rea, Thomas D.

Mayo Clinic

Journal of the American Heart Association | January 19, 2024 | Volume: 13 | Issue: 3 | Pages: No page available

10.1161/jaha.122.028902 | PMID 38240206 Get It

Background Sex‐specific risk management may improve outcomes in congenital long QT syndrome (LQTS). We recently developed a prediction score for cardiac events (CEs) and life‐threatening events (LTEs) in postadolescent women with LQTS. In the present study, we aimed to develop personalized risk estimates for the burden of CEs and LTEs in male adolescents with potassium channel‐mediated LQTS. Methods and Results The prognostic model was derived from the LQTS Registry headquartered in Rochester, NY, comprising 611 LQT1 or LQT2 male adolescents from age 10 through 20 years, using the following variables: genotype/mutation location, QTc‐specific thresholds, history of syncope, and β‐blocker therapy. Anderson‐Gill modeling was performed for the end point of CE burden (total number of syncope, aborted cardiac arrest, and appropriate defibrillator shocks). The applicability of the CE prediction model was tested for the end point of the first LTE (excluding syncope and adding sudden cardiac death) using Cox modeling. A total of 270 CEs occurred during follow‐up. The genotype–phenotype risk prediction model identified low‐, intermediate‐, and high‐risk groups, comprising 74%, 14%, and 12% of the study population, respectively. Compared with the low‐risk group, high‐risk male subjects experienced a pronounced 5.2‐fold increased risk of recurrent CEs ( P <0.001), whereas intermediate‐risk patients had a 2.1‐fold ( P =0.004) increased risk . At age 20 years, the low‐, intermediate‐, and high‐risk adolescent male patients had on average 0.3, 0.6, and 1.4 CEs per person, respectively. Corresponding 10‐year adjusted probabilities for a first LTE were 2%, 6%, and 8%. Conclusions Personalized genotype–phenotype risk estimates can be used to guide sex‐specific management in male adolescents with potassium channel‐mediated LQTS.
Clinical Management of Brugada Syndrome: Commentary From the Experts
Cutler, Michael J. , Eckhardt, Lee L. , Kaufman, Elizabeth S. , Arbelo, Elena , Behr, Elijah R. , Brugada, Pedro , Crotti, Lia , Asmundis, Carlo de , Horie, Minoru , Huang, David T. , Lubitz, Steven A. , Mackall, Judith A. , Roden, Dan M. , Sacher, Frédéric , Shoemaker, Benjamin, Sy, Raymond W. , Watanabe, Atsuyuki , Wilde, Arthur A.M. , Cerrone, Marina , Crotti, Lia , deAsmundis, Carlo , Gollob, Michael H , Horie, Minoru , Huang, David T , Krahn, Andrew D , London, Barry , Lubitz, Steven A , Mackall, Judith A , Nademanee, Koonlawee , Perez, Marco V , Probst, Vincent , Roden, Dan M. , Sacher, Frederic , Sarquella-Brugada, Georgia , Scheinman, Melvin M , Shimizu, Wataru , Shoemaker, M Benjamin , Sy, Raymond W , Wilde, Arthur A M , Behr, Elijah Raphael , Eckhardt, Lee L , Arbelo, Elena , Cerrone, Marina , Gollob, Michael H. , Krahn, Andrew D. , London, Barry , Nademanee, Koonlawee , Pérez, Marco

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | December 15, 2023 | Volume: 17 | Issue: 1 | Pages: No page available

10.1161/circep.123.012072 | PMID 38099441 Get It

Although there is consensus on the management of patients with Brugada Syndrome with high risk for sudden cardiac arrest, asymptomatic or intermediate-risk patients present clinical management challenges. This document explores the management opinions of experts throughout the world for patients with Brugada Syndrome who do not fit guideline recommendations. Four real-world clinical scenarios were presented with commentary from small expert groups for each case. All authors voted on case-specific questions to evaluate the level of consensus among the entire group in nuanced diagnostic and management decisions relevant to each case. Points of agreement, points of controversy, and gaps in knowledge are highlighted.
Executive Summary: Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Neurology, Peri-Transplant Medicine, Infectious Disease, and Gastroenterology Considerations
Nanchal, Rahul , Subramanian, Ram, Alhazzani, Waleed , Dionne, Joanna C. , Peppard, William , Truwit, Jonathon D. , Al‐Khafaji, Ali , Killian, Alley , Alquraini, Mustafa , Alshammari, Khalil, Alshamsi, Fayez , Cartin‐Ceba, Rodrigo , Hollenberg, Steven M. , Galusca, Dragos, Hyzy, Robert C., Kandiah, Prem , Kumar, Gagan , Morris, Peter E. , Olson, Jody C. , Sieracki, Rita , Steadman, Randolph H., Karvellas, Constantine , Karvellas, Constantine , Singbartl, Kai , Belley‐Côté, Emilie P. , Huang, David T. , Junek, Mats , Morgan, Rebecca L. , Taylor, Beth

Mayo Clinic

Critical Care Medicine | April 13, 2023 | Volume: 51 | Issue: 5 | Pages: 653-656

10.1097/ccm.0000000000005825 | PMID 37052435 Get It

Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Neurology, Peri-Transplant Medicine, Infectious Disease, and Gastroenterology Considerations
Nanchal, Rahul , Subramanian, Ram, Alhazzani, Waleed , Dionne, Joanna C. , Peppard, William , Truwit, Jonathon D. , Al‐Khafaji, Ali , Killian, Alley , Alquraini, Mustafa , Alshammari, Khalil, Alshamsi, Fayez , Cartin‐Ceba, Rodrigo , Hollenberg, Steven M. , Galusca, Dragos, Hyzy, Robert C., Kandiah, Prem , Kumar, Gagan , Morris, Peter E. , Olson, Jody C. , Sieracki, Rita , Steadman, Randolph H., Karvellas, Constantine , Karvellas, Constantine , Singbartl, Kai , Belley‐Côté, Emilie P. , Huang, David T. , Junek, Mats , Morgan, Rebecca L. , Taylor, Beth

Mayo Clinic

Critical Care Medicine | April 13, 2023 | Volume: 51 | Issue: 5 | Pages: 657-676

10.1097/ccm.0000000000005824 | PMID 37052436 Get It

OBJECTIVES: To develop evidence-based recommendations for clinicians caring for adults with acute liver failure (ALF) or acute on chronic liver failure (ACLF) in the ICU. DESIGN: The guideline panel comprised 27 members with expertise in aspects of care of the critically ill patient with liver failure or methodology. We adhered to the Society of Critical Care Medicine standard operating procedures manual and conflict-of-interest policy. Teleconferences and electronic-based discussion among the panel, as well as within subgroups, served as an integral part of the guideline development. INTERVENTIONS: In part 2 of this guideline, the panel was divided into four subgroups: neurology, peri-transplant, infectious diseases, and gastrointestinal groups. We developed and selected Population, Intervention, Comparison, and Outcomes (PICO) questions according to importance to patients and practicing clinicians. For each PICO question, we conducted a systematic review and meta-analysis where applicable. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach. We used the evidence to decision framework to facilitate recommendations formulation as strong or conditional. We followed strict criteria to formulate best practice statements. MEASUREMENTS AND MAIN RESULTS: We report 28 recommendations (from 31 PICO questions) on the management ALF and ACLF in the ICU. Overall, five were strong recommendations, 21 were conditional recommendations, two were best-practice statements, and we were unable to issue a recommendation for five questions due to insufficient evidence. CONCLUSIONS: Multidisciplinary, international experts formulated evidence-based recommendations for the management ALF and ACLF patients in the ICU, acknowledging that most recommendations were based on low quality and indirect evidence.
Utility of Biomarkers for Sepsis-Associated Acute Kidney Injury Staging
Molinari, Luca , Smith, A.J. Conrad , Landsittel, Douglas , Singbartl, Kai , Yealy, Donald M., Kellum, John A. , Investigators, ProCESS and ProGReSS-AKI, Keener, Christopher, Lucko, Nicole, Pike, Francis, Yende, Sachin , Gimbel, Elizabeth, Landis, Kyle, Stapleton, Diana K., Weissfeld, Lisa A., Willochell, Michael, Wofford, Kourtney A., Watts, Hannah , Venkat, Arvind , Hou, Peter C. , Massaro, Anthony F., Parmar, Siddharth , Brewer, Kori L. , Delbridge, Theodore R. , Mainhart, Allison, Miner, James R. , Allen, Todd L., Grissom, Colin K. , Swadron, Stuart P., Carlson, Richard, LoVecchio, Frank , Parry, Blair A. , Ellender, Timothy J., Sama, Andrew E., Fine, Jonathan , Nafeei, Soheil, Wojnar, Margaret, Pearl, Ronald G. , Wilber, Scott T., Sinert, Richard , Orban, David J., Ufberg, Jacob W. , Albertson, Timothy, Panacek, Edward A., Parekh, Sohan, Gunn, Scott R. , Rittenberger, Jon S., Wadas, Richard J. , Edwards, Andrew R., Holmes, T., Weinert, Craig , Harris, Estelle S. , Self, Wesley H. , Dubinski, Diane, Phillips, Carolyn, Migues, Ronald M., Singbartl, Kai , Kellum, John A , Rio‐Pertuz, Gaspar Del , Palevsky, Paul M. , Chawla, Lakhmir S. , Huang, David T. , Angus, Derek C. , Investigators, ProCESS and ProGReSS-AKI, Barnato, Amber E. , Eaton, Tammy L. , Kulstad, Erik Benjamin , Limkakeng, Alexander T. , Conrad, Steven A. , Bajwa, Ednan K. , Filbin, Michael R. , Terndrup, Thomas E. , Wilson, Jason W. , Kelly, Matthew, Wang, Henry E. , McCurdy, Michael T. , Phillips, Carolyn A

Mayo Clinic

JAMA Network Open | May 18, 2022 | Volume: 5 | Issue: 5 | Pages: e2212709

10.1001/jamanetworkopen.2022.12709 | PMID 35583867 Get It

Subcutaneous ICD combined with VT ablation for the secondary prevention of sudden cardiac death: pilot data from the prospective multinational SICD-VTAbl study
Sacher, F., Mulpuru, Siva K. , Friedman, Paul A. , Meyer, Christopher , Benshushan, Abraham, Tiefenbrun, Nava L., Nof, Eyal , Investigators, The SICD-VTAbl, Goldenberg, Ilan , Maury, Philippe , Clémenty, Nicolas , Huang, David T. , Meyer, C, Benshushan, A D, Tiefenbrun, Nava, Investigators, The SICD-VTAbl

Mayo Clinic

European Heart Journal | October 20, 2021 | Volume: 42 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehab724.0399 Get It

Abstract Background The aim of the Subcutaneous ICD Combined with Ventricular Tachycardia Ablation (SICD-VTAbl) Study is to provide preliminary data on the safety and efficacy of a management strategy that incorporates S-ICD implantation and VT ablation among patients with a secondary prevention indication for an ICD. We hypothesize that VT ablation for the prevention of monomorphic VT recurrence combined with S-ICD implantation for termination of life-threatening VT/VF is safe, while reducing the need for device interventions and systemic complications associated with conventional transvenous ICD implantation for secondary prevention. Methods SICD-VTAbl is an uncontrolled, prospective, multinational observational study, conducted in France, Germany, US (Rochester NY, and Rochester MN) and coordinated in Israel. We aim to prospectively enroll 30 patients presenting with scar-related VT/VF who will undergo VT ablation/substrate modification followed by S-ICD implantation. The primary endpoint is the first occurrence of S-ICD therapy (appropriate and inappropriate). Secondary endpoints include separate occurrence of appropriate and inappropriate ICD therapies, peri-procedural complications, and adverse clinical outcomes. Results We provide clinical, arrhythmia, and outcome data on the first 15 patients enrolled in the SICD-VTAbl Study through February 2021. Mean age was 59±12 years, 78% were males, 60% had New York Heart Association (NYHA) Class ≥II symptoms, 20% had renal insufficiency, and 33% were treated with an antiarrhythmic medication (all amiodarone). Periprocedural, arrhythmia, and long-term outcome data are provided in Table 1. There were no major complications associated with the VT ablation and the S-ICD implantation procedures. During a median follow-up of 6 months (interquartile range: 2–12 months), 2 patients (13%) received S-ICD therapy: one patient (7%) experienced VF terminated by the S-ICD and one patient experienced a single episode of inappropriate S-ICD therapy. Adverse events during follow-up, unrelated to study procedures, occurred in 3 patients (20%): hospitalization for heart failure exacerbation (N=1) and non-cardiovascular hospitalizations (N=2). None of the patients died during follow-up (Table 1). Conclusions Our preliminary data from the SICD-VTAbl Study suggest that a management approach that incorporates VT ablation followed by S-ICD implantation is safe and may lead to improved arrhythmia and clinical outcomes in patients presenting with a secondary prevention indication for an ICD. Funding Acknowledgement Type of funding sources: Other. Main funding source(s): Research grant to Sheba Medical Center from Boston Scientific
Risk Prediction in Women With Congenital Long QT Syndrome
Bos, J. Martijn , Yoruk, Ayhan , Chen, Anita Y. , Lopes, Coeli M. , Huang, David T. , Kutyifa, Valentina , Aktaş, Mehmet K. , Rosero, Spencer , McNitt, Scott , Sotoodehnia, Nona , Kudenchuk, Peter J. , Arking, Dan E. , Briske, Kaylie A., Sorensen, Katrina B. , Ackerman, Michael J. , Zaręba, Wojciech , Sorensen, Katrina, J Ackerman, Michael, Bos, Johan M , Huang, David T , Zareba, Wojciech , Goldenberg, Ilan , Younis, Arwa , Rea, Thomas D. , Scott, Christopher G.

Mayo Clinic

Journal of the American Heart Association | July 9, 2021 | Volume: 10 | Issue: 14 | Pages: No page available

10.1161/jaha.121.021088 | PMID 34238014 Get It

Background We aimed to provide personalized risk estimates for cardiac events (CEs) and life‐threatening events in women with either type 1 or type 2 long QT. Methods and Results The prognostic model was derived from the Rochester Long QT Syndrome Registry, comprising 767 women with type 1 long QT (n=404) and type 2 long QT (n=363) from age 15 through 60 years. The risk prediction model included the following variables: genotype/mutation location, QTc‐specific thresholds, history of syncope, and β‐blocker therapy. A model was developed with the end point of CEs (syncope, aborted cardiac arrest, or long QT syndrome–related sudden cardiac death), and was applied with the end point of life‐threatening events (aborted cardiac arrest, sudden cardiac death, or appropriate defibrillator shocks). External validation was performed with data from the Mayo Clinic Genetic Heart Rhythm Clinic (N=467; type 1 long QT [n=286] and type 2 long QT [n=181]). The cumulative follow‐up duration among the 767 enrolled women was 22 243 patient‐years, during which 323 patients (42%) experienced ≥1 CE. Based on genotype‐phenotype data, we identified 3 risk groups with 10‐year projected rates of CEs ranging from 15%, 29%, to 51%. The corresponding 10‐year projected rates of life‐threatening events were 2%, 5%, and 14%. C statistics for the prediction model for the 2 respective end points were 0.68 (95% CI 0.65–0.71) and 0.71 (95% CI 0.66–0.76). Corresponding C statistics for the model in the external validation Mayo Clinic cohort were 0.65 (95% CI 0.60–0.70) and 0.77 (95% CI 0.70–0.84). Conclusions This is the first risk prediction model that provides absolute risk estimates for CEs and life‐threatening events in women with type 1 or type 2 long QT based on personalized genotype‐phenotype data. The projected risk estimates can be used to guide female‐specific management in long QT syndrome.
Serial Measurement of Cell-Cycle Arrest Biomarkers [TIMP-2] · [IGFBP7] and Risk for Progression to Death, Dialysis, or Severe Acute Kidney Injury in Patients with Septic Shock
Fiorentino, Marco , Xu, Zhongying , Smith, A.J. Conrad , Singbartl, Kai , Yealy, Donald M., Kellum, John A. , Chawla, Lakhmir S. , Kellum, John A , Singbartl, Kai , Palevsky, Paul M. , Huang, David T. , Angus, Derek C.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 25, 2020 | Volume: 202 | Issue: 9 | Pages: 1262-1270

10.1164/rccm.201906-1197oc | PMID 32584598 Get It

Abstract Rationale Urinary TIMP-2 (tissue inhibitor of metalloproteinases-2) and IGFBP7 (insulin-like growth factor–binding protein 7) can predict acute kidney injury (AKI) in patients with sepsis. Objectives To address critical questions about whether biomarkers can inform the response to treatment and whether they might be used to guide therapy, as most sepsis patients present with AKI. Methods We measured [TIMP-2] · [IGFBP7] before and after a 6-hour resuscitation in 688 patients with septic shock enrolled in the ProCESS (Protocol-based Care for Early Septic Shock) trial. Our primary endpoint was stage 3 AKI, renal replacement therapy, or death within 7 days. Measurements and Main Results: The endpoint was reached in 113 patients (16.4%). In patients with negative [TIMP-2] · [IGFBP7] at baseline, those who became positive (&gt;0.3 U) after resuscitation had three-times higher risk compared with those who remained negative (21.8% vs. 8.5%; P = 0.01; odds ratio [OR], 3.0; 95% confidence interval [CI], 1.31–6.87). Conversely, compared with patients with a positive biomarker at baseline that were still positive at Hour 6, risk was reduced for patients who became negative (23.8% vs. 9.8%; P = 0.01; OR, 2.15; 95% CI, 1.17–3.95). A positive [TIMP-2] · [IGFBP7] after resuscitation was associated with worse outcomes in both patients with and without AKI at that time point. The clinical response to resuscitation, as judged by the Acute Physiology and Chronic Health Evaluation II score, was weakly predictive of the endpoint (area under the curve, 0.68; 95% CI, 0.62–0.73) and improved with addition of [TIMP-2] · [IGFBP7] (0.72; 95% CI, 0.66–0.77; P = 0.03). Different resuscitation protocols did not alter biomarker trajectories, nor did they alter outcomes in biomarker-positive or biomarker-negative patients. However, biomarker trajectories were associated with outcomes. Conclusions Changes in urinary [TIMP-2] · [IGFBP7] after initial fluid resuscitation identify patients with sepsis who have differing risk for progression of AKI. Clinical trial registered with www.clinicaltrials.gov (NCT 00510835).